Introduction COVID-19 vaccines have been highly effective in reducing morbidity and
mortality during the pandemic. However, the emergence of the Omicron variant and …

Importance Estimates of the rate of waning of vaccine effectiveness (VE) against COVID-19
are key to assess population levels of protection and future needs for booster doses to face …

Background Synthesising evidence on the long-term vaccine effectiveness of COVID-19
vaccines (BNT162b2 [Pfizer–BioNTech], mRNA-1273 [Moderna], ChAdOx1 nCoV-19 …

Infection with SARS-CoV-2 is associated with an increased risk of arterial and venous
thrombotic events, but the implications of vaccination for this increased risk are uncertain …

The first dose of COVID-19 vaccines led to an overall reduction in cardiovascular events,
and in rare cases, cardiovascular complications. There is less information about the effect of …

Background COVID-19 is a respiratory illness caused by SARS-CoV-2. The most recent
variant is Omicron (line B. 1.1. 529), which was first identified in South Africa in November …

Background Booster COVID-19 vaccines have shown efficacy in clinical trials and
effectiveness in real-world data against symptomatic and severe illness. However, some …

Background Some studies have shown that the incidence of type 2 diabetes increases after
a diagnosis of COVID-19, although the evidence is not conclusive. However, the effects of …

Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) persistence in COVID‐19
patients could play a key role in the emergence of variants of concern. The rapid intra‐host …

Background The COVID-19 pandemic led to the rapid development and deployment of
several highly effective vaccines against SARS-CoV-2. Recent studies suggest that these …